image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - CA
$ 1.37
3.2 %
$ 4.98 M
Market Cap
-0.18
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SBFM stock under the worst case scenario is HIDDEN Compared to the current market price of 1.37 USD, Sunshine Biopharma, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SBFM stock under the base case scenario is HIDDEN Compared to the current market price of 1.37 USD, Sunshine Biopharma, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SBFM stock under the best case scenario is HIDDEN Compared to the current market price of 1.37 USD, Sunshine Biopharma, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SBFM

image
$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
34.9 M REVENUE
44.75%
-5.81 M OPERATING INCOME
-21.46%
-5.13 M NET INCOME
-13.94%
-12.5 M OPERATING CASH FLOW
-42.80%
-2.32 M INVESTING CASH FLOW
-253.71%
9.29 M FINANCING CASH FLOW
171.18%
9.59 M REVENUE
13.75%
-2.04 M OPERATING INCOME
-84.18%
-2.16 M NET INCOME
-80.18%
-3.41 M OPERATING CASH FLOW
-150.36%
-532 K INVESTING CASH FLOW
8.10%
2.05 M FINANCING CASH FLOW
10.08%
Balance Sheet Sunshine Biopharma, Inc.
image
Current Assets 26 M
Cash & Short-Term Investments 9.69 M
Receivables 3.87 M
Other Current Assets 12.4 M
Non-Current Assets 4.59 M
Long-Term Investments 0
PP&E 1.48 M
Other Non-Current Assets 3.11 M
31.70 %12.66 %40.61 %4.85 %10.18 %Total Assets$30.6m
Current Liabilities 6.31 M
Accounts Payable 5.54 M
Short-Term Debt 208 K
Other Current Liabilities 564 K
Non-Current Liabilities 745 K
Long-Term Debt 745 K
Other Non-Current Liabilities 0
78.52 %2.94 %7.99 %10.55 %Total Liabilities$7.1m
EFFICIENCY
Earnings Waterfall Sunshine Biopharma, Inc.
image
Revenue 34.9 M
Cost Of Revenue 24.2 M
Gross Profit 10.7 M
Operating Expenses 17.4 M
Operating Income -5.81 M
Other Expenses -678 K
Net Income -5.13 M
35m35m30m30m25m25m20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)35m(24m)11m(17m)(6m)678k(5m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
30.60% GROSS MARGIN
30.60%
-16.67% OPERATING MARGIN
-16.67%
-14.72% NET MARGIN
-14.72%
-21.85% ROE
-21.85%
-16.80% ROA
-16.80%
-22.73% ROIC
-22.73%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sunshine Biopharma, Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -5.13 M
Depreciation & Amortization 224 K
Capital Expenditures 0
Stock-Based Compensation 0
Change in Working Capital -5.38 M
Others -3.26 M
Free Cash Flow -12.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sunshine Biopharma, Inc.
image
SBFM has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Sunshine Biopharma, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion FORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Everolimus in the Canadian generic prescription drugs market. Everolimus is a generic equivalent of the brand name Afinitor®. accessnewswire.com - 1 week ago
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering FORT LAUDERDALE, FL / ACCESS Newswire / April 3, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced the closing of the previously announced registered direct offering with institutional investors of approximately $2.46 million of shares of Common Stock and pre-funded warrants at a price of $2.07 per share of Common Stock. The entire transaction was priced at the market under Nasdaq rules. accessnewswire.com - 4 weeks ago
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that it has entered into definitive agreements in a registered direct offering with institutional investors for the purchase and sale of approximately $2.46 million of shares of Common Stock and pre-funded warrants at a price of $2.07 per share of Common Stock. The entire transaction has been priced at the market under Nasdaq rules. accessnewswire.com - 1 month ago
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug Sunshine Biopharma Inc. SBFM traded higher on Wednesday, with a session volume of 19.07 million compared to an average volume of 88.16K, according to data from Benzinga Pro. benzinga.com - 1 month ago
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("We", "Our", the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid Nanoparticle (K1.1-mRNA-LNP) product as a novel therapeutic agent for human hepatocellular carcinoma. Human hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. accessnewswire.com - 1 month ago
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year FORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 annual report on Form 10-K on Tuesday, April 1, 2025. The following are highlights of the report: Revenue in 2024 grew to $34.9 million, a 45% increase over 2023 revenue of $24.1 million. accessnewswire.com - 1 month ago
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada FORT LAUDERDALE, FL / ACCESS Newswire / March 24, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that is has signed a strategic agreement granting it the rights to market two new generic antibiotics in Canada. The Company anticipates launching these new products through its wholly-owned Canadian subsidiary, Nora Pharma, in the next six to nine months following regulatory approval. accessnewswire.com - 1 month ago
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market FORT LAUDERDALE, FL / ACCESS Newswire / March 10, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has acquired the rights to two gastrointestinal drugs and already launched one. The second is planned to be launched in the next 9 months. accessnewswire.com - 1 month ago
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs. The newly launched drugs are Olanzapine and Olanzapine ODT. accessnewswire.com - 3 months ago
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pleased to announce the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. accesswire.com - 3 months ago
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has developed an orally active protease inhibitor with dose-dependent antiviral activity in mice infected with SARS Coronavirus (SARS-CoV-2). There are still unmet medical needs for agents to combat SARS-CoV-2 infections. accesswire.com - 4 months ago
Sunshine Biopharma Launches a New Generic Prescription Drug FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched a new generic prescription drug. The newly launched drug is Ursodiol, a generic version of URSO DS®. accesswire.com - 5 months ago
8. Profile Summary

Sunshine Biopharma, Inc. SBFM

image
COUNTRY CA
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 4.98 M
Dividend Yield 0.00%
Description Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Contact 6500 Trans-Canada Highway, Pointe-Claire, QC, H9R 0A5 https://www.sunshinebiopharma.com
IPO Date Feb. 15, 2022
Employees 52
Officers Dr. Abderrazzak Merzouki Chief Operating Officer & Director Mr. Michel Roy Chief Commercial Officer Mr. Camille Sebaaly Chief Financial Officer & Secretary Mr. Robert G. Ferreira President of Sunshine Bio Investments Inc Mr. Malek Chamoun Chief Development Officer Dr. Steve N. Slilaty Ph.D. Chairman, President & Chief Executive Officer